anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the relentless pursuit of optimizing drug development, the intricate process of determining the ideal dosage unfolds. This involves "dose-finding" studies, crucial for providing insights into subsequent registration trials. However, the challenges intensify when tackling rare diseases. The complexity arises from poorly understood pathophysiologies, scarcity of appropriate animal models, and limited natural history understanding. The inherent heterogeneity, coupled with challenges in defining clinical end points, poses substantial challenges, hindering the utility of available data. The small affected population, low disease awareness, and restricted healthcare access compound the difficulty in conducting dose-finding studies. This white paper delves into critical dose selection aspects, focusing on key therapeutic areas, such as oncology, neurology, hepatology, metabolic rare diseases. It also explores dose selection challenges posed by pediatric rare diseases as well as novel modalities, including enzyme replacement therapies, cell and gene therapies, and oligonucleotides. Several examples emphasize the pivotal role of clinical pharmacology in navigating the complexities associated with these diseases and emerging treatment modalities.
The present invention provides purified polypeptides which comprise at least a portion of a .delta. T cell receptor polypeptide, a .gamma. T cell receptor polypeptide, a .gamma. , .delta. T cell receptor complex or a .gamma. , .delta. T cell receptor complex.      Substances capable of forming complexes with these polypeptides are also provided.      Additionally, methods for detecting T cells which have within them or on their surfaces a polypeptide of the present invention are provided. Moreover, methods for diagnosing immune system abnormalities are provided which comprise measuring in a sample from a subject the number of T cells which have within them or on their surfaces a polypeptide of the present invention.
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules contain mixed salts of a single-entity amphetamine, a CNS stimulant. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules contain equal amounts (by weight) of four salts: dextroamphetamine sulfate and amphetamine sulfate, dextroamphetamine saccharate and amphetamine aspartate monohydrate. This results in a 3:1 mixture of dextro- to levo- amphetamine base equivalent. 

The 12.5 mg, 25 mg, 37.5 mg and 50 mg strength capsules are for oral administration. They are designed to contain two types of drug extended release pellets. One type of extended release pellets contains an outer coating of drug to immediately release drug upon administration.

Inactive Ingredients: ethylcellulose, hypromellose 2910, iron oxide red, iron oxide yellow, methacrylic acid copolymer dispersion; methyl acrylate, methyl methacrylate, and methacrylic acid copolymer; polyethylene glycol 400, polysorbate 80, sugar spheres (which contains corn starch and sucrose), talc, titanium dioxide, and triethyl citrate. The capsule shells contain gelatin, sodium lauryl sulfate, titanium dioxide. In addition, the 12.5 mg capsule shell contains carboxymethylcellulose, iron oxide red, and iron oxide yellow; the 25 mg capsule shell contains carboxymethylcellulose, FD&C Blue #1, iron oxide red, and iron oxide yellow; the 37.5 mg capsule shell contains carboxymethylcellulose, FD&C Blue #1and FD&C Red #40, and iron oxide red; 50 mg capsule shell contains FD&C Blue #1 and FD&C Red #40. The printing ink for 12.5 mg, 25 mg, and 37.5 mg capsule contains ammonium hydroxide, iron oxide black, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution. The printing ink for the 50 mg capsule contains ammonium hydroxide, povidone, propylene glycol, simethicone (which contains dimethicone and silicon dioxide), shellac, sodium hydroxide, and titanium dioxide.
Tendons are fibrous connective tissues that transmit force from muscles to bones. Despite their ability to withstand various loads, tendons are susceptible to significant damage. The healing process of tendons and ligaments connected to bone surfaces after injury presents a clinical challenge due to the intricate structure, composition, cellular populations, and mechanics of the interface. Inflammation plays a pivotal role in tendon healing, creating an inflammatory microenvironment through cytokines and immune cells that aid in debris clearance, tendon cell proliferation, and collagen fiber formation. However, uncontrolled inflammation can lead to tissue damage, and adhesions, and impede proper tendon healing, culminating in scar tissue formation. Therefore, precise regulation of inflammation is crucial. This review offers insights into the impact of inflammation on tendon-bone healing and its underlying mechanisms. Understanding the inflammatory microenvironment, cellular interactions, and extracellular matrix dynamics is essential for promoting optimal healing of tendon-bone injuries. The roles of fibroblasts, inflammatory cytokines, chemokines, and growth factors in promoting healing, inhibiting scar formation, and facilitating tissue regeneration are discussed, highlighting the necessity of balancing the suppression of detrimental inflammatory responses with the promotion of beneficial aspects to enhance tendon healing outcomes. Additionally, the review explores the significant implications and translational potential of targeted inflammatory modulation therapies in refining strategies for tendon-bone healing treatments.
These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
Participants in the DBP will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks. In the optional OLE, all participants will receive Lu AF82422 IV infusion starting on Day 1 of the OLE up to week 92.
Through screening of an expression library, a cDNA sequence has been identified that encodes a protein that interacts with human CD33, the DNA being highly homologous to a portion of the human dystrophin gene. A region of that cDNA has been identified as an important regulatory element in controlling expression, both transcription and translation, of the DNA with which it is associated. This DNA sequence element may be used as a regulatory cassette in conjunction with any suitable gene, to modify gene expression. The putative controlling DNA sequence element contains a minimum of 137 base pairs (FIG.  1 ) to 147 base pairs (FIG.  1 A) and a maximum of 287 base pairs (FIG.  1 B).
OBJECTIVE: To describe clinical, laboratory, and antibiotic treatment characteristics in pregnant or recently pregnant women diagnosed with maternal sepsis.
METHODS: A retrospective cohort study was conducted in a Brazilian tertiary hospital from March 2014 until February 2018. The hospital implemented a Sepsis Protocol, based on the Brazilian Ministry of Health recommendation. All women who were pregnant or recently pregnant (up to 42 days postpartum), and who presented with suspected sepsis were included. Unconfirmed infections were excluded. Three hundred sixty-five women were included and divided into three groups according to sepsis severity (SEPSIS-2): sepsis, severe sepsis, and septic shock. Clinical, laboratory, and management characteristics were described and compared.
RESULTS: Pregnancy-related and respiratory tract infections were the greater causes of maternal sepsis, and the urinary tract was the major cause of septic shock. We found almost total compliance with blood culture sample collection, and samples were positive in 10.8% of the cases, and in 41% of septic shock patients. Escherichia coli was the most common pathogen found and it was resistant to third-generation cephalosporins in none of the blood cultures and 3.3% of the urine cultures. Using the AWaRe (Access, Watch and Reserve) classification groups of antibiotics, Access and Watch antibiotics were used in virtually all women. We did not find any fatal maternal outcomes.
CONCLUSION: Maternal sepsis is seldom the result of resistant microorganisms in this setting and the use of Access group antibiotics is widely possible. Health professionals' awareness of and institutional policies for maternal sepsis are crucial to its adequate treatment and better outcomes.
The experimental group intervened a dance somatosensory game (DSG), DANZ BASE developed by International Games System Company, at the Xinzhuang health center, which is a local bureau with outpatient clinic. The participants in experimental group played twice a week, each time requiring at least lasting 30 minutes, for half of a year.
The invention relates to a traditional Chinese medicine used for treating prostatitis. The traditional Chinese medicine is prepared from the medicine materials of: 3-7g of realgar, 4-15g of Japanese climbing fern spore, 4-10g of banksian rose, 4-10 parts of Asiatic plantain seed, and 5-15g of raw rehmannia rhizome. The materials are grinded into fine powder, and the powder is divided into 4 parts. Each part is 1 preparation, and 1 preparation is taken each day. The preparation is directly swollen or taken in capsules. According to the formula, the formulation is simple, medicine amount is low, and the medicine materials are all common traditional Chinese medicines. The administration method is convenient and diverse. The preparation can be prepared into pills, capsules, and powders. However, the preparation is not suitable for decoction.
In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
The present invention can inhibit dihydrofolate reductase in a microorganism. In some aspects, it may also suppress pigment formation in gram negative bacteria. The suppression of pigment formation can also mediate virulence suppression on other Gram negative bacteria. As such, the compounds may be used for microbial infections. The compounds can potentiate the effects of one or more antimicrobial agents when co-administered. Compositions including the compounds are provided. The composition can further include at least one antibiotic.
The Halt-intervention is a widely used Dutch diversion measure for youth (aged 12-17) who committed a minor offence. In the current study, it will be investigated whether the Halt-intervention is successful in reducing recidivism and in achieving the intervention goals. The effectiveness will be assessed using a randomized controlled trial. Participants will be randomly assigned to the experimental condition in which participants will receive the halt intervention or to the control condition in which participants will not receive an intervention. Participants fill out three self-reported questionnaires over a time period of one year. With these questionnaires is it investigated whether the intervention is successful in achieving the different intervention goals (improving social skills, taking responsibility, correct wrongdoing or damage, improving conventional beliefs and improving support from the social network) and in achieving a reduction in recidivism. Furthermore, the adherence to children's rights in the practice of Halt is investigated. Lastly, two years after the first contact with Halt recidivism is assessed using official police and judicial records.
Sophoridine (SRP) is a natural quinolizidine alkaloid found in many traditional Chinese herbs, though its effect on adipose tissue is unclear. We improved serum lipid levels by administering SRP by gavage in high-fat diet (HFD)-fed C57BL/6 mice. After 11 weeks, SRP supplementation significantly reduced body weight gain and improved glucose homeostasis, while reducing subcutaneous fat and liver weight. SRP also inhibited cell proliferation and differentiation of 3T3-L1 cells. Proteomics analysis revealed that SRP inhibits adipocyte differentiation by interacting with Src, thereby suppressing vascular endothelial growth factor receptor 2 (VEGFR2) expression and PI3K/AKT phosphorylation. This study provides an empirical basis for the treatment of obesity with small molecules.
The adverse reactions listed below have been observed in controlled and uncontrolled clinical trials in approximately 700 patients who received acyclovir at approximately 5 mg/kg (250 mg/m2) three times daily, and approximately 300 patients who received approximately 10 mg/kg (500 mg/m2) three times daily.

The most frequent adverse reactions reported during administration of acyclovir were inflammation or phlebitis at the injection site in approximately 9% of the patients, and transient elevations of serum creatinine or BUN in 5% to 10% (the higher incidence occurred usually following rapid [less than 10 minutes] intravenous infusion). Nausea and/or vomiting occurred in approximately 7% of the patients (the majority occurring in nonhospitalized patients who received 10 mg/kg). Itching, rash, or hives occurred in approximately 2% of patients. Elevation of transaminases occurred in 1% to 2% of patients.

The following hematologic abnormalities occurred at a frequency of less than 1%: anemia, neutropenia, thrombocytopenia, thrombocytosis, leukocytosis, and neutrophilia. In addition, anorexia and hematuria were observed.
The present report describes a case of acanthocephaliasis associated with necrotic enteritis in quetzals (Pharomachrus mocinno). Three juvenile quetzals exhibited depression, anorexia, ruffled feathers, and sudden death. They were submitted to the laboratory for examination. The birds had hatched and lived in captivity in an aviary in Mexico. Gross lesions observed were hemorrhagic, fibrinoid necrotic enteritis, with acanthocephalans adhered to the intestinal mucosa. The specimens were identified by parasitology, electronic microscopy, and molecular biology as Plagiorhynchus (Prosthorhynchus) sp. Lesions compatible with necrotic enteritis were also confirmed by isolation and genotyping of Clostridium perfringens type E. This is the first report of Plagiorhynchus (Prosthorhynchus) sp. in quetzals in captivity in Mexico. The findings in this manuscript suggest that this parasite could be a predisposing factor for necrotic enteritis as well as a risk component in the breeding programs and survival of this avian species in captivity.
Methadone Hydrochloride Oral Concentrate, USP dye-free, sugar-free, unflavored contains methadone, an opioid agonist, and is available as a dye-free, sugar-free, unflavored liquid concentrate of methadone hydrochloride for oral administration. 

Methadone hydrochloride is chemically described as 6-(dimethylamino)-4,4-diphenyl-3-heptone hydrochloride. Methadone hydrochloride, USP is a fine white powder. It is very soluble in water, soluble in isopropanol and in chloroform, and practically insoluble in ether and in glycerine. It is present in Methadone Hydrochloride as the racemic mixture. Methadone hydrochloride has a melting point of 235°C, a pKa of 8.25 in water at 20°C, a solution (1 part per 100) pH between 4.5 and 6.5, a partition coefficient of 117 at pH 7.4 in octanol/water and a molecular weight of 345.91. Its structural formula is C21H27NO•HCl.

This liquid concentrate contains 10 mg of methadone hydrochloride (equivalent to 8.95 mg of methadone) per mL and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate.
Tell-show-do play therapy initiative will be applied to children included in intervention group 1. The initiative will be applied to children without disturbing the parent-child relationship. The intervention will be applied for 10-15 minutes. The tell-show-do play therapy initiative will be implemented using the directed play therapy method and therapeutic play tools. Amigurumi dolls, medical toys (surgical shirt, movable toy bed) and real medical materials such as stethoscope, patient armband, bone, mask, degree will be used as therapeutic play tools.
IMPORTANCE: Paroxysmal supraventricular tachycardia (PSVT), defined as tachyarrhythmias that originate from or conduct through the atria or atrioventricular node with abrupt onset, affects 168 to 332 per 100 000 individuals. Untreated PSVT is associated with adverse outcomes including high symptom burden and tachycardia-mediated cardiomyopathy.
OBSERVATIONS: Approximately 50% of patients with PSVT are aged 45 to 64 years and 67.5% are female. Most common symptoms include palpitations (86%), chest discomfort (47%), and dyspnea (38%). Patients may rarely develop tachycardia-mediated cardiomyopathy (1%) due to PSVT. Diagnosis is made on electrocardiogram during an arrhythmic event or using ambulatory monitoring. First-line acute therapy for hemodynamically stable patients includes vagal maneuvers such as the modified Valsalva maneuver (43% effective) and intravenous adenosine (91% effective). Emergent cardioversion is recommended for patients who are hemodynamically unstable. Catheter ablation is safe, highly effective, and recommended as first-line therapy to prevent recurrence of PSVT. Meta-analysis of observational studies shows single catheter ablation procedure success rates of 94.3% to 98.5%. Evidence is limited for the effectiveness of long-term pharmacotherapy to prevent PSVT. Nonetheless, guidelines recommend therapies including calcium channel blockers, β-blockers, and antiarrhythmic agents as management options.
CONCLUSION AND RELEVANCE: Paroxysmal SVT affects both adult and pediatric populations and is generally a benign condition. Catheter ablation is the most effective therapy to prevent recurrent PSVT. Pharmacotherapy is an important component of acute and long-term management of PSVT.
Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
Leukocytes, which may include one or more of monocytes, macrophages, lymphocytes, and neutrophils, are harvested and administered to a region of the body. In the preferred embodiment, leukocytes are harvested from the blood by plasmapherisis, a procedure known to those familiar with blood-banking techniques, and used to treat an intervertebral disc. Plasmapherisis allows the removal of desired blood component(s) from a larger volume of blood than the technique described in the '000 Application. Returning the non-desired blood components to the patient prior to withdraw of additional blood prevents complications that may occur from hypovolemia. Thus, a larger number of leukocytes can be obtained with plasmapherisis than with centrifugation of blood removed during a single blood withdraw. Plasmapherisis can also be used to harvest platelets to treat DDD, HNP and other non-disc-related conditions.
PURPOSE: A composition and a cosmetic composition containing ethanol extract of Angelicae Sinensis Radix for treating leukemia are provided to inhibit the growth of leukemia cells and to effectively treat and prevent leukemia. CONSTITUTION: A composition for preventing and treating leukemia contains ethanol extract of Angelicae Sinensis Radix as an active ingredient. The ethanol extract is prepared by extracting Angelicae Sinensis Radix at 50 Deg. C for 24 hours and drying and concentrating at 45 Deg. C and reduce pressure. The ethanol is 95% ethanol. The composition also contains pharmaceutically acceptable carriers or diluents. The composition is acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia. A cosmetic composition for preventing leukemia contains the ethanol extract of cosmetically acceptable cosmetically acceptable additive.
Chronic wounds are a major healthcare burden and may severely affect the social, mental, and economic status of the patients. Any impairment in wound healing stages due to underlying factors leads to a prolonged healing time and subsequently to chronic wounds. Traditional approaches for the treatment of chronic wounds include dressing free local therapy, dressing therapy, and tissue engineering based scaffold therapies. However, traditional therapies need improvisation and have been advanced through breakthrough technologies. The present review spans traditional therapies and further gives an extensive account of advancements in the treatment of chronic wounds. Cutting edge technologies, such as 3D printing, which includes inkjet printing, fused deposition modeling, digital light processing, extrusion-based printing, microneedle array-based therapies, gene therapy, which includes microRNAs (miRNAs) therapy, and smart wound dressings for real time monitoring of wound conditions through assessment of pH, temperature, oxygen, moisture, metabolites, and their use for planning of better treatment strategies have been discussed in detail. The review further gives the future direction of treatments that will aid in lowering the healthcare burden caused due to chronic wounds.
FIELD: biotechnology; medicine; agriculture.SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Gene-therapeutic DNA vector based on a genotyping DNA vector GDTT1.8NAS12, wherein the gene-therapeutic DNA vector GDTT1.8NAS12-IFNB1 contains a coding portion of the desired IFNB1 gene cloned into the genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 1, gene-therapeutical DNA vector GDTT1.8NAS12-IFNA14 contains a coding part of the target IFNA14 gene cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 2, gene-therapeutic DNA vector GDTT1.8NAS12-IFNA2 contains a coding part of the target IFNA2 gene cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 3, gene-therapeutic DNA vector GDTT1.8NAS12-IL12A contains a coding part of the target gene IL12A, cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 4, gene-therapeutic DNA vector GDTT1.8NAS12-IL12B contains a coding part of the target gene IL12B, cloned into a genotyping DNA-vector GDTT1.8NAS12, with a nucleotide sequence SEQ ID No.5.EFFECT: treating the diseases characterized by congenital and adaptive immunity disorders for the therapy of autoimmune, oncological, viral diseases associated with immune system imbalance, for immunomodulation including in anticancer vaccination as a gene therapeutic adjuvant.16 cl, 17 dwg, 23 ex